New drug treatments for urinary incontinence

Maturitas

Volumn 65, Issue 4, 2010, Pages 340-347

  Robinson, Dudley ^a   Cardozo, Linda ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Drug therapy; Overactive bladder; Stress incontinence; Urinary incontinence

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIDIURETIC AGENT; DARIFENACIN; DESMOPRESSIN; DULOXETINE; ESTRADIOL; ESTROGEN DERIVATIVE; FESOTERODINE; IMIPRAMINE; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PLACEBO; PROPIVERINE; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

BEHAVIOR THERAPY; BLURRED VISION; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONSTIPATION; ESTROGEN THERAPY; HUMAN; LOWER URINARY TRACT SYMPTOM; NAUSEA; OVERACTIVE BLADDER; QUALITY OF LIFE; REVIEW; STRESS INCONTINENCE; UNSPECIFIED SIDE EFFECT; URGE INCONTINENCE; URINE INCONTINENCE; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; ANTIDIURETIC AGENTS; ANTIMUTAGENIC AGENTS; ESTROGENS; FEMALE; HUMANS; PRACTICE GUIDELINES AS TOPIC; THIOPHENES; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 77949267044     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2009.12.022     Document Type: Review

References (97)

1. Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology of lower urinary tract function. Report from the standardisation committee of the International Continence Society. Neurourol Urodynam 21 (2002) 167-178
2. Kelleher C.J., Cardozo L.D., Khullar V., and Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 104 (1997) 1374-1379
3. Hannestad Y.S., Rortveit G., Sandvik H., and Hunskar S. A community-based epidemiological survey of female urinary incontinence: The Norwegian EPINCONT Study. J Clin Epidemiol 53 (2000) 1150-1157
4. Stewart W.F., Corey R., Herzog A.R., et al. Prevalence of overactive bladder in women: results from the NOBLE program. Int Urogynaecol J 12 3 (2001) S66
5. Milsom I., Abrams P., Cardozo L., Roberts R.G., Thuroff J., and Wein A.J. How widespread are the symptoms of overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87 9 (2001) 760-766
6. Irwin D.E., Milsom I., Hunskaar S., et al. Population-based survey of urinary incontinence, overactive bladder and other lower urinary tract symptoms in five countries; results of the EPIC study. Eur Urol (2006) [Epub ahead of print]
7. Andersson K.-E. The overactive bladder: pharmacologic basis of drug treatment. Urology 50 6A Suppl. (1997) 74-84
8. Waldeck K., Larsson B., and Andersson K.E. Comparison of oxybutynin and it's active metabolite, N-desmethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 157 (1997) 1093-1097
9. Hughes K.M., Lang J.C.T., Lazare R., et al. Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 22 (1992) 859-869
10. Cardozo L.D., Cooper D., and Versi E. Oxybutynin chloride in the management of idiopathic detrusor instability. Neurourol Urodyn 6 (1987) 256-257
11. Baigrie R.J., Kelleher J.P., Fawcett D.P., and Pengelly A.W. Oxybutynin: is it safe?. Br J Urol 62 (1988) 319-322
12. Anderson R.U., Mobley D., Blank B., et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J Urol 161 6 (1999) 1809-1812
13. Gleason D.M., Susset J., White C., et al. Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Urology 54 3 (1999) 420-423
14. Dmochowski R.R., Sand P.K., Zinner N.R., et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 62 2 (2003) 237-242
15. Staskin D.R., Dmochowski R.R., Sand P.K., et al. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomised, double blind, placebo controlled, multicentre study. J Urol 181 (2009) 1764-1772
16. Haruno A., Yamasaki Y., Miyoshi K., et al. Effects of propiverine hydrochloride and its metabolites on isolated guinea pig urinary bladder. Folia Pharmacol Jpn 94 (1989) 145-150
17. Mazur D., Wehnert J., Dorschner W., Schubert G., Herfurth G., and Alken R.G. Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence. Scand J Urol Nephrol 29 (1995) 289-294
18. Stoher M., Madersbacher H., Richter R., Wehnert J., and Dreikorn K. Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia: a double-blind, placebo-controlled clinical trial. Spinal Cord 37 3 (1999) 196-200
19. Thuroff J.W., Chartier-Castler E., Corcos J., et al. Medical treatment and medical side effects in urinary incontinence in the elderly. World J Urol 16 Suppl. 1 (1998) S48
20. Ruscin J.M., and Morgenstern N.E. Tolterodine use for symptoms of overactive bladder. Ann Pharmacother 33 10 (1999) 1073-1082
21. Nilvebrant L., Andersson K.-E., Gillberg P.-G., Stahl M., and Sparf B. Tolterodine-a new bladder selective antimuscarinic agent. Eur J Pharmacol 327 (1997) 195-207
22. Nilvebrant L., Hallen B., and Larsson G. Tolterodine-a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci 60 13-14 (1997) 1129-1136
23. Hills C.J., Winter S.A., and Balfour J.A. Tolterodine Drugs 55 (1998) 813-820
24. Jonas U., Hofner K., Madesbacher H., and Holmdahl T.H. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. World J Urol 15 (1997) 144-151
25. Millard R., Tuttle J., Moore K., et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol 161 5 (1999) 1551-1555
26. Rentzhog L., Stanto S.L., Cardozo L.D., Nelson E., Fall M., and Abrams P. Efficacy and safety of tolterodine in patients with detrusor instability: a dose ranging study. Br J Urol 81 1 (1998) 42-48
27. Appell R.A. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a poled analysis. Urology 50 (1997) 90-96
28. Swift S., Garely A., Dimpfl T., Payne C., and Tolterodine Study Group. A new once daily formulation of tolterodine provides superior efficacy an is well tolerated in women with overactive bladder. Int J Pelvic Floor Dysfunct 14 1 (2003) 50-54
29. Van Kerrebroeck P., Kreder K., Jonas U., Zinner N., Wein A., and Tolterodine Study Group. Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology 57 3 (2001) 414-421
30. Diokno A.C., Appell R.A., Sand P.K., et al. Prospective, randomised, double blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 78 6 (2003) 687-695
31. Schladitz-Keil G., Spahn H., and Mutschler E. Determination of bioavailability of the quaternary ammonium compound trospium chloride in man from urinary excretion data. Arzneimittel Forsch/Drug Res 36 (1986) 984-987
32. Fusgen I., and Hauri D. Trospium chloride: an effective option for medical treatment of bladder overactivity. Int J Clin Pharmacol Ther 38 5 (2000) 223-234
33. Cardozo L.D., Chapple C.R., Toozs-Hobson P., et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial. BJU Int 85 6 (2000) 659-664
34. Staskin D.R., Sand P., Zinner N., Dmochowski R., and Trospium Study Group. Once daily Trospium chloride is effective and well tolerated for the treatment of overactive bladder; results from a multicentre phase III trial. J Urol 178 (2007) 978-983
35. Dmochowski R.R., Sand P.K., Zinner N.R., and Staskin D.R. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo controlled interventional study. Urology 71 (2008) 449-454
36. Dmochowski R.R., Rosenberg M.T., Zinner N.R., Staskin D.R., and Sand P.K. Extended release trospium chloride improves quality of life in overactive bladder. Value Health (2009) [Epub October 2009]
37. Cardozo L., Lisec M., Millard R., et al. Randomised, double blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 172 (2004) 1919-1924
38. Chapple C.R., Arano P., Bosch J.L., De Ridder D., Kramer A.E., and Ridder A.M. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo and tolterodine controlled phase II dose-finding study. BJU Int 93 (2004) 71-77
39. Haab F., Cardozo L., Chapple C., Ridder A.M., and Solifenacin Study Group. Long-term open label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 47 (2005) 376-384
40. Chapple C.R., Martinez-Garcia R., Selvaggi L., et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 48 (2005) 464-470
41. Chapple C.R., Artibani W., Cardozo L.D., et al. The role of urinary urgency and its measurement in the overactive bladder syndrome: current concepts and future prospects. BJU Int 95 (2005) 335-340
42. Cardozo L., Hebdorfer E., Milani R., et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder; results from a randomised, double-blind, placebo-controlled, rising dose trial. BJU Int 102 (2008) 1120-1127
43. Toglia M., Andoh M., and Hussain I. Solifenacin improved warning time significantly compared to placebo in patients with overactive bladder. Neurourol Urodynam 25 (2006) 655
44. Cardozo L., and Dixon A. Increased warning time with Darifenacin: a new concept in the management of urinary urgency. J Urol 173 (2005) 1214-1218
45. Karram M.M., and Chancellor M. Solifenacin treatment reduces symptoms of overactive bladder in patients with residual urgency on tolterodine treatment: results of the VERSUS study. Int Urogynaecol J 17 Suppl 3 (2006) S441
46. Wagg A., Wyndaele J.J., and Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 4 (2006) 14-24
47. Wesnes K., Edgar C., Tretter R., Patel H., and Bolodeoku J. Solifenacin is not associated with cognitive impairment or sedation in the elderly. The randomised double-blind SCOPE study. Poster presentation. 38th Annual meeting of the international continence society. Cairo, Egypt (2008)
48. Mattiason A., Morton A., and Bolodeoku J. Solifenacin alone and with simplified bladder retraining in overactive bladder syndrome: The prospective randomised SOLAR study. Poster presentation. 38th Annual meeting of the international continence society. Cairo, Egypt (2008)
49. Garley A.D., Kaufman J.M., Sand P.K., Smith N., and Andoh M. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the Vesicare Open Label Trial. Clin Ther 28 (2006) 1935-1946
50. Alabaster V.A. Discovery and development of selective M3 antagonists for clinical use. Life Sci. 60 13-14 (1997) 1053-1060
51. Haab F., Stewart L., and Dwyer P. Darifenacin an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 45 4 (2004 Apr) 420-429
52. Chapple C.R. Darifenacin is well tolerated and provides significant improvement in the symptoms of overactive bladder: a pooled analysis of phase III studies. J Urol 171 Suppl (2004) 130 [abstract 487]
53. Malhotra B., Gandelman K., Sachse R., Wood N., and Michel M.C. The design and development of Fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem 16 (2009) 4481-4489
54. Chapple C., and Fesoterodine:. A new effective and well tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a phase II controlled study. Neurourol Urodyn 23 5/6 (2004) 598-599
55. Chapple C., Van Kerrebroeck P., Tubaro A., and Millard R. Fesoterodine in non-neurogenic voiding dysfunction-results on efficacy and safety in a phase III trial. Eur Urol Suppl 5 2 (2006) 117
56. Chapple C.R., Van Kerrebroeck P.E., Junemann K.P., Wang J.T., and Brodsky M. Comparison of Fesoterodine and tolterodine in patients with overactive bladder. BJU Int 102 (2008) 1128-1132
57. Kelleher C.J., Tubaro A., Wang J.T., and Kopp Z. Impact of Fesoterodine on quality of life: pooled data from two randomised trials. BJU Int 102 (2008) 56-61
58. Baldessarini K.J. Drugs in the treatment of psychhiatric disorders. In: Gilman, et al. (Ed). The pharmacological basis of theraputics. 7th ed. (1985), McMillan Publishing Co. 387-445
59. Castleden C.M., Duffin H.M., and Gulati R.S. Double-blind study of imipramine and placebo for incontinence due to bladder instability. Age Aging 15 (1986) 299-303
60. Diokno Ac, Hyndman C.W., Hardy D.A., and Lapides J. Comparison of action of imipramine (Tofranil) and propantheline (Probanthine) on detrusor contraction. J Urol 107 (1972) 42-43
61. Norgaard J.P., Rillig S., and Djurhuus J.C. Nocturnal enuresis: an approach to treatment based on pathogenesis. J Pediatrics 114 (1989) 705-709
62. Mattiasson A., Abrams P., Van Kerrebroeck P., Walter S., and Weiss J. Efficacy of Desmopressin in the treatment of nocturia: a double blind placebo controlled studying men. BJU Int 89 (2002) 855-862
63. Robinson D., Cardozo L., Akeson M., Hvistendahl G., Riis A., and Norgaard J. Women take control; Desmopressin-a drug for daytime urinary incontinence. Neurourol Urodyn 21 4 (2002) 385-386
64. NICE Guideline 40. The management of urinary incontinence in women (2006), Department of Health. www.nice.org.uk
65. Thor K.B., and Katofiasc M.A. Effects of Duloxetine, a combined serotonin and norepineephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetised female cat. J Pharmacol Exp Ther 274 (1995) 1014-1024
66. Norton P.A., Zinner N.R., Yalcin I., Bump R.C., and Duloxetine Urinary Incontinence Study Group. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynaecol 187 1 (2002) 40-48
67. Millard R., Moore K., Yalcin I., and Bump R. Duloxetine vs. placebo in the treatment of stress urinary incontinence: a global phase III study. Neurourol Urodynam 22 (2003) 482-483
68. Cardozo L., Drutz H.P., Baygani S.K., and Bump R.C. Pharmacological treatment of women awaiting surgery for stress urinary incontinence. Obstet Gynaecol 104 (2004) 511-519
69. Ghoniem G.M., Van Leeuwen J.S., Elser D.M., et al. A randomised controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. J Urol 173 (2005) 1453-1454
70. Salmon U.L., Walter R.I., and Gast S.H. The use of oestrogen in the treatment of dysuria and incontinence in postmenopausal women. Am J Obstet Gynaecol 14 (1941) 23-31
71. Youngblood V.H., Tomlin E.M., and Davis J.B. Senile urethritis in women. J Urol 78 (1957) 150-152
72. Grady D., Brown J.S., Vittinghoff E., Applegate W., Varner E., and Synder T. Postmenopausal hormones and incontinence: the Heart and Estrogen/progestin Replacement Study. Obstet Gynaecol 97 (2001) 116-120
73. Grodstein F., Lifford K., Resnick N.M., and Curhan G.C. Postmenopausal hormone therapy and risk of developing urinary incontinence. Obstet Gynaecol 103 (2004) 254-260
74. Ouslander J.G., Greendale G.A., Uman G., Lee C., Paul W., and Schnelle J. Effects of oral oestrogen and progestin on the lower urinary tract among female nursing home residents. Am Geriatr Soc 49 6 (2001) 803-807
75. Hendrix S.L., Cochrane B.R., Nygaard I.E., et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA 293 8 (2005) 935-948
76. Caine M, Raz S. The role of female hormones in stress incontinence. In: Proceedings of the 16th congress of the international society of urology, Amsterdam, The Netherlands.
77. Rud T. The effects of oestrogens and gestagens on the urethral pressure profile in urinary continent and stress incontinent women. Acta Obstet Gynaecol Scand 59 (1980) 265-270
78. Wilson P.D., Faragher B., Butler B., Bullock D., Robinson E.L., and Brown A.D.G. Treatment with oral piperazine oestrone sulphate for genuine stress incontinence in postmenopausal women. Br J Obstet Gynaecol 94 (1987) 568-574
79. Walter S., Wolf H., Barlebo H., and Jansen H. Urinary incontinence in postmenopausal women treated with oestrogens: a double-blind clinical trial. J Urol 33 (1978) 135-143
80. Fantl J.A., Bump R.C., Robinson D., et al. Efficacy of oestrogen supplementation in the treatment of urinary incontinence. Obstet Gynaecol 88 (1996) 745-749
81. Jackson S., Shepherd A., Brookes S., and Abrams P. The effect of oestrogen supplementation on post-menopausal urinary stress incontinence: a double-blind, placebo controlled trial. Br J Obstet Gynaecol 106 (1999) 711-718
82. Sultana C.J., and Walters M.D. Oestrogen and urinary incontinence in women. Maturitas 20 (1995) 129-138
83. Samsicoe G., Jansson I., Mellstrom D., and Svanberg A. Urinary incontinence in 75 year old women. Effects of oestriol. Acta Obstet Gynaecol Scand 93 (1985) 57
84. Cardozo L.D., Rekers H., Tapp A., et al. Oestriol in the treatment of postmenopausal urgency: a multicentre study. Maturitas 18 (1993) 47-53
85. Nilsson K., and Heimer G. Low dose oestradiol in the treatment of urogenital oestrogen deficiency-a pharmacokinetic and pharmacodynamic study. Maturitas 15 (1992) 121-127
86. Benness C., Wise B.G., Cutner A., and Cardozo L.D. Does low dose vaginal oestradiol improve frequency and urgency in postmenopausal women. Int Urogynaecol J 3 2 (1992) 281
87. Eriksen P.S., and Rasmussen H. Low dose 17β-oestradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study. Eur J Obstet Gynaecol Reprod Biol 44 (1992) 137-144
88. Lose G., and Englev E. Oestradiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms. Br J Obstet Gynaecol 107 (2000) 1029-1034
89. Cardozo L., Lose G., McClish D., and Versi E. Estrogen treatment for symptoms of an overactive bladder, results of a meta analysis. Int J Urogynaecol 12 3 (2001) V
90. Cody J.D., Richardson K., Moehrer B., Hextall A., and Glazener C.M.A. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database of Systematic Reviews 4 (2009) Art. No: CD001405. DOI: 10.1002/14651858.CD001405.pub2
91. Levin R.M., Kitada S., Hayes L., et al. Experimental hyperreflexia: effect of intravesical administration of various agents. Pharmacology 42 (1991) 54
92. Andersson K.E. The overactive bladder: pharmacologic basis of drug treatment. Urology 50 (1997) 74
93. Laval K.U., and Lutzeyer W. Spontaneous phasic activity of the detrusor: a cause of uninhibited contractions in unstable bladder. Urol Int 35 (1980) 182-187
94. Chapple C., Patroneva A., and Raines S. Effect of an ATP-sensitive potassium channel opener in subjects with overactive bladder: a randomized double-blind placebo controlled study (ZD0947IL/0004). Eur Urol (2006) 879-886
95. Green S.A., Alon A., Ianus J., Mc Naughton, Tozzi C.A., and Reiss T.F. Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence. J Urol 176 (2006) 2535-2540
96. Colli E., Digesu G.A., and Olivieri L. Overactive bladder treatments in early phase clinical trials. Exp Opin Invest Drugs 16 (2007) 999-1007
97. Chapple C.R., Yamaguchi O., and Ridder A. Clinical proof of concept study (Blossom) shows novel β3 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder. Eur Urol Suppl 7 (2008) 239